Twenty-four-hour hemodynamic profile during treatment of essential hypertension by once-a-day nadolol.
- 1 July 1983
- journal article
- research article
- Published by Wolters Kluwer Health in Hypertension
- Vol. 5 (4) , 573-578
- https://doi.org/10.1161/01.hyp.5.4.573
Abstract
The effect of nadolol (N) on 24-hour blood pressure (BP) and heart rate (HR) values and on their variability was examined in ambulant patients with essential hypertension, using the Oxford method to obtain continuous intraarterial recording and a computer to have a beat-to-beat analysis of the data. The recording was carried out without treatment and after 10 days' administration of N once daily by mouth (dose range: 80-320 mg). After N, 24-hour BP and HR were reduced by 17 +/- 3% and 27 +/- 4% respectively as compared to before N, the effect being similar for both systolic and diastolic BP. The hypertension and bradycardia were significantly more marked during the day than during the night, neither showing any attenuation in the hours furthest from the administration of the drug. During N, there was a reduction in the 24-hour variation coefficient for HR but the reduction was limited to the longer term component of this phenomenon, the moment-to-moment variations remaining unaffected. The long- and short-term variation coefficients for BP were not modified under N. These findings suggest that N once a day can reduce BP for 24 hours in ambulant hypertensive patients. The lack of alteration in variability of BP and moment-to-moment HR suggests that the hypotension is achieved without interfering with the mechanisms involved in cardiovascular homeostasis.This publication has 15 references indexed in Scilit:
- Blood pressure response to labetalol in twice and three times daily administration during a 24-hour period.Published by Wiley ,1982
- DOES PLACEBO LOWER BLOOD-PRESSURE?The Lancet, 1981
- Timolol-Induced Reduction in Mortality and Reinfarction in Patients Surviving Acute Myocardial InfarctionNew England Journal of Medicine, 1981
- NadololDrugs, 1980
- CORONARY HEART-DISEASE AFTER TREATMENT OF HYPERTENSIONThe Lancet, 1978
- Dose-ranging study of the new beta-adrenergic antagonist nadolol in the treatment of essential hypertensionCurrent Medical Research and Opinion, 1978
- Metabolic Studies in Patients with Nadolol: Oral and Intravenous AdministrationThe Journal of Clinical Pharmacology, 1977
- Pharmacology of nadolol (SQ 11725), a β-adrenergic antagonist lacking direct myocardial depressionEuropean Journal of Pharmacology, 1975
- Continuous recording of direct arterial pressure in unrestricted patients. Its role in the diagnosis and management of high blood pressure.Circulation, 1975